Extracellular release of HMGB1 in disease pathogenesis, such as sepsis, arthritis, colitis, and ischemia reperfusion, has validated that the inhibition of HMGB1 significantly reduces the severity of many of these conditions [35,44,45,46]. This evidence concerns the gene HMGB1 and Sepsis.